Patents by Inventor Julianna Lisziewicz
Julianna Lisziewicz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240000911Abstract: The disclosure relates to polypeptides and pharmaceutical compositions comprising polypeptides that find use in the prevention or treatment of cancer, in particular gastric cancer, lung cancer, melanoma and bladder cancer. The disclosure also relates to methods of inducing a cytotoxic T cell response in a subject or treating cancer by administering pharmaceutical compositions comprising the peptides, and companion diagnostic methods of identifying subjects for treatment. The peptides comprise T cell epitopes that are immunogenic in a high percentage of patients.Type: ApplicationFiled: May 2, 2023Publication date: January 4, 2024Inventors: Julianna Lisziewicz, Levente Molnár, Eniko Toke, József Toth, Orsolya Lorincz, Zsolt Csiszovszki, Eszter Somogyi, Katalin Pántya, Mónika Megyesi
-
Publication number: 20230405100Abstract: The disclosure relates to polypeptides and pharmaceutical compositions comprising polypeptides that find use in the prevention or treatment of cancer, in particular breast cancer, ovarian cancer and colorectal cancer. The disclosure also relates to methods of inducing a cytotoxic T cell response in a subject or treating cancer by administering pharmaceutical compositions comprising the peptides, and companion diagnostic methods of identifying subjects for treatment. The peptides comprise T cell epitopes that are immunogenic in a high percentage of patients.Type: ApplicationFiled: February 8, 2023Publication date: December 21, 2023Inventors: Julianna Lisziewicz, Levente Molnár, Eniko R. Toke, József Toth, Orsolya Lorincz, Zsolt Csiszovszki, Eszter Somogyi, Katalin Pántya, Mónika Megyesi
-
Patent number: 11666644Abstract: The disclosure relates to polypeptides and pharmaceutical compositions comprising polypeptides that find use in the prevention or treatment of cancer, in particular gastric cancer, lung cancer, melanoma and bladder cancer. The disclosure also relates to methods of inducing a cytotoxic T cell response in a subject or treating cancer by administering pharmaceutical compositions comprising the peptides, and companion diagnostic methods of identifying subjects for treatment. The peptides comprise T cell epitopes that are immunogenic in a high percentage of patients.Type: GrantFiled: September 3, 2019Date of Patent: June 6, 2023Assignee: Treos Bio LimitedInventors: Julianna Lisziewicz, Levente Molnar, Eniko Toke, József Toth, Orsolya Lorincz, Zsolt Csiszovszki, Eszter Somogyi, Katalin Pantya, Mónika Megyesi
-
Patent number: 11628211Abstract: The disclosure relates to polypeptides and pharmaceutical compositions comprising polypeptides that find use in the prevention or treatment of cancer, in particular breast cancer, ovarian cancer and colorectal cancer. The disclosure also relates to methods of inducing a cytotoxic T cell response in a subject or treating cancer by administering pharmaceutical compositions comprising the peptides, and companion diagnostic methods of identifying subjects for treatment. The peptides comprise T cell epitopes that are immunogenic in a high percentage of patients.Type: GrantFiled: December 22, 2021Date of Patent: April 18, 2023Assignee: Treos Bio LimitedInventors: Julianna Lisziewicz, Levente Molnár, Eniko R. Toke, József Toth, Orsolya Lorincz, Zsolt Csiszovszki, Eszter Somogyi, Katalin Pántya, Mónika Megyesi
-
Patent number: 11426452Abstract: The disclosure relates to polypeptides and pharmaceutical compositions comprising polypeptides that find use in the prevention or treatment of cancer, in particular breast cancer, ovarian cancer and colorectal cancer. The disclosure also relates to methods of inducing a cytotoxic T cell response in a subject or treating cancer by administering pharmaceutical compositions comprising the peptides, and companion diagnostic methods of identifying subjects for treatment. The peptides comprise T cell epitopes that are immunogenic in a high percentage of patients.Type: GrantFiled: December 22, 2021Date of Patent: August 30, 2022Assignee: Treos Bio LimitedInventors: Julianna Lisziewicz, Levente Molnár, Eniko R. Toke, József Toth, Orsolya Lorincz, Zsolt Csiszovszki, Eszter Somogyi, Katalin Pántya, Mónika Megyesi
-
Publication number: 20220160854Abstract: The disclosure relates to polypeptides, polynucleic acids and pharmaceutical compositions comprising polypeptides that find use in the prevention or treatment of cancer. The disclosure also relates to methods of inducing a cytotoxic T cell response in a subject or treating cancer by administering pharmaceutical compositions comprising the peptides, and companion diagnostic methods. The disclosure also relates to a method of preparing a peptide or polynucleic acid for use in a method of inducing a T cell response against a target polypeptide, wherein the method comprises identifying epitopes in the antigen that bind to multiple alleles of receptors of the highest proportion of subjects in a target population.Type: ApplicationFiled: February 8, 2022Publication date: May 26, 2022Inventors: Levente Molnár, Eniko R. Toke, Julianna Lisziewicz, József Tóth, Orsolya Lorincz, Zsolt Csiszovszki, Eszter Somogyi, Katalin Pántya, Mónika Megyesi, Péter Páles
-
Publication number: 20220111024Abstract: The disclosure relates to polypeptides and pharmaceutical compositions comprising polypeptides that find use in the prevention or treatment of cancer, in particular breast cancer, ovarian cancer and colorectal cancer. The disclosure also relates to methods of inducing a cytotoxic T cell response in a subject or treating cancer by administering pharmaceutical compositions comprising the peptides, and companion diagnostic methods of identifying subjects for treatment. The peptides comprise T cell epitopes that are immunogenic in a high percentage of patients.Type: ApplicationFiled: December 22, 2021Publication date: April 14, 2022Inventors: Julianna Lisziewicz, Levente Molnár, Eniko R. Toke, József Toth, Orsolya Lorincz, Zsolt Csiszovszki, Eszter Somogyi, Katalin Pántya, Mónika Megyesi
-
Publication number: 20220111025Abstract: The disclosure relates to polypeptides and pharmaceutical compositions comprising polypeptides that find use in the prevention or treatment of cancer, in particular breast cancer, ovarian cancer and colorectal cancer. The disclosure also relates to methods of inducing a cytotoxic T cell response in a subject or treating cancer by administering pharmaceutical compositions comprising the peptides, and companion diagnostic methods of identifying subjects for treatment. The peptides comprise T cell epitopes that are immunogenic in a high percentage of patients.Type: ApplicationFiled: December 22, 2021Publication date: April 14, 2022Inventors: Julianna Lisziewicz, Levente Molnár, Eniko R. Toke, József Toth, Orsolya Lorincz, Zsolt Csiszovszki, Eszter Somogyi, Katalin Pántya, Mónika Megyesi
-
Publication number: 20220072114Abstract: The disclosure relates to methods of identifying fragments of a polypeptide that are immunogenic for a specific human subject, methods of preparing pharmaceutical compositions comprising such polypeptide fragments, pharmaceutical compositions comprising such polypeptide fragments, and methods of treatment using such compositions. The methods comprise identifying a fragment of the polypeptide that binds to multiple HLA of individual subjects.Type: ApplicationFiled: November 9, 2021Publication date: March 10, 2022Inventors: Julianna Lisziewicz, Levente Molnár, Eniko R. Toke, József Toth, Orsolya Lorincz, Zsolt Csiszovszki, Eszter Somogyi, Katalin Pántya, Mónika Megyesi
-
Publication number: 20220031823Abstract: The disclosure relates to methods of identifying fragments of a polypeptide that are immunogenic for a specific human subject, methods of preparing personalised pharmaceutical compositions comprising such polypeptide fragments, human subject-specific pharmaceutical compositions comprising such polypeptide fragments, and methods of treatment using such compositions. The methods comprise identifying a fragment of the polypeptide that binds to multiple HLA of the subject.Type: ApplicationFiled: September 17, 2021Publication date: February 3, 2022Inventors: Julianna Lisziewicz, Levente Molnár, Eniko R. Toke, József Toth, Orsolya Lorincz, Zsolt Csiszovszki, Eszter Somogyi, Katalin Pántya, Mónika Megyesi
-
Patent number: 11213578Abstract: The disclosure relates to polypeptides and pharmaceutical compositions comprising polypeptides that find use in the prevention or treatment of cancer, in particular breast cancer, ovarian cancer and colorectal cancer. The disclosure also relates to methods of inducing a cytotoxic T cell response in a subject or treating cancer by administering pharmaceutical compositions comprising the peptides, and companion diagnostic methods of identifying subjects for treatment. The peptides comprise T cell epitopes that are immunogenic in a high percentage of patients.Type: GrantFiled: January 10, 2019Date of Patent: January 4, 2022Assignee: Treos Bio LimitedInventors: Julianna Lisziewicz, Levente Molnár, Enikő R. Tőke, József Toth, Orsolya Lorincz, Zsolt Csiszovszki, Eszter Somogyi, Katalin Pántya, Mónika Megyesi
-
Publication number: 20210236611Abstract: The disclosure relates to polypeptides, polynucleic acids and pharmaceutical compositions comprising polypeptides that find use in the prevention or treatment of cancer. The disclosure also relates to methods of inducing a cytotoxic T cell response in a subject or treating cancer by administering pharmaceutical compositions comprising the peptides, and companion diagnostic methods. The disclosure also relates to a method of preparing a peptide or polynucleic acid for use in a method of inducing a T cell response against a target polypeptide, wherein the method comprises identifying epitopes in the antigen that bind to multiple alleles of receptors of the highest proportion of subjects in a target population.Type: ApplicationFiled: February 26, 2021Publication date: August 5, 2021Inventors: Levente MOLNÁR, Eniko R. TOKE, Julianna LISZIEWICZ, József TÓTH, Orsolya LORINCZ, Zsolt CSISZOVSZKI, Eszter SOMOGYI, Katalin PÁNTYA, Mónika MEGYESI, Péter PÁLES
-
Publication number: 20190240302Abstract: The disclosure relates to polypeptides and pharmaceutical compositions comprising polypeptides that find use in the prevention or treatment of cancer, in particular breast cancer, ovarian cancer and colorectal cancer. The disclosure also relates to methods of inducing a cytotoxic T cell response in a subject or treating cancer by administering pharmaceutical compositions comprising the peptides, and companion diagnostic methods of identifying subjects for treatment. The peptides comprise T cell epitopes that are immunogenic in a high percentage of patients.Type: ApplicationFiled: January 10, 2019Publication date: August 8, 2019Inventors: Julianna LISZIEWICZ, Levente MOLNÁR, Eniko R. TOKE, József TOTH, Orsolya LORINCZ, Zsolt CSISZOVSZKI, Eszter SOMOGYI, Katalin PÁNTYA, Mónika MEGYESI
-
Patent number: 10213497Abstract: The disclosure relates to polypeptides and pharmaceutical compositions comprising polypeptides that find use in the prevention or treatment of cancer, in particular breast cancer, ovarian cancer and colorectal cancer. The disclosure also relates to methods of inducing a cytotoxic T cell response in a subject or treating cancer by administering pharmaceutical compositions comprising the peptides, and companion diagnostic methods of identifying subjects for treatment. The peptides comprise T cell epitopes that are immunogenic in a high percentage of patients.Type: GrantFiled: March 2, 2018Date of Patent: February 26, 2019Assignee: TREOS BIO ZRT.Inventors: Julianna Lisziewicz, Levente Molnár, Eniko R. Toke, József Toth, Orsolya Lorincz, Zsolt Csiszovszki, Eszter Somogyi, Katalin Pántya, Mónika Megyesi
-
Publication number: 20180264094Abstract: The disclosure relates to methods of identifying fragments of a polypeptide that are immunogenic for a specific human subject, methods of preparing personalised pharmaceutical compositions comprising such polypeptide fragments, human subject-specific pharmaceutical compositions comprising such polypeptide fragments, and methods of treatment using such compositions. The methods comprise identifying a fragment of the polypeptide that binds to multiple HLA of the subject.Type: ApplicationFiled: March 2, 2018Publication date: September 20, 2018Inventors: Julianna LISZIEWICZ, Levente MOLNÁR, Enikö R. TÖKE, József TOTH, Orsolya LORINCZ, Zsolt CSISZOVSZKI, Eszter SOMOGYI, Katalin PÁNTYA, Mónika MEGYESI
-
Publication number: 20180264095Abstract: The disclosure relates to methods of identifying fragments of a polypeptide that are immunogenic for a specific human subject, methods of preparing pharmaceutical compositions comprising such polypeptide fragments, pharmaceutical compositions comprising such polypeptide fragments, and methods of treatment using such compositions. The methods comprise identifying a fragment of the polypeptide that binds to multiple HLA of individual subjects.Type: ApplicationFiled: March 2, 2018Publication date: September 20, 2018Inventors: Julianna LISZIEWICZ, Levente MOLNÁR, Enikõ R. TÖKE, József TOTH, Orsolya LORINCZ, Zsolt CSISZOVSZKI, Eszter SOMOGYI, Katalin PÁNTYA, Mónika MEGYESI
-
Publication number: 20180250399Abstract: The disclosure relates to polypeptides and pharmaceutical compositions comprising polypeptides that find use in the prevention or treatment of cancer, in particular breast cancer, ovarian cancer and colorectal cancer. The disclosure also relates to methods of inducing a cytotoxic T cell response in a subject or treating cancer by administering pharmaceutical compositions comprising the peptides, and companion diagnostic methods of identifying subjects for treatment. The peptides comprise T cell epitopes that are immunogenic in a high percentage of patients.Type: ApplicationFiled: March 2, 2018Publication date: September 6, 2018Inventors: Julianna Lisziewicz, Levente Molnár, Enikö R. Töke, József Toth, Orsolya Lorincz, Zsolt Csiszovszki, Eszter Somogyi, Katalin Pántya, Mónika Megyesi
-
Patent number: 7910562Abstract: A molecular delivery complex specific to antigen-presenting cells is formed from a non-viral gene delivery system complexed with foreign genetic material. The complex then enters the targeted cells through a specific receptor and overcomes the degradation mechanism, so that functional uptake of the foreign genetic material, or transduction, of the cell, results in gene expression. The invention also includes a method for genetic immunization without a needle.Type: GrantFiled: February 21, 2002Date of Patent: March 22, 2011Assignee: Genetic Immunity, LLCInventors: Julianna Lisziewicz, Franco Lori
-
Publication number: 20090263828Abstract: Diagnostic assay of antigen-specific T-cell precursors to determine the immunological status of patients suffering in chronic infectious diseases and to anticipate the disease progression and the response to therapyType: ApplicationFiled: April 16, 2009Publication date: October 22, 2009Inventors: Franco Lori, Sandra A. Calarota, Julianna Lisziewicz
-
Publication number: 20080234215Abstract: A plasmid DNA that encodes one or more antigenic genes operably linked to a promoter and a truncated retroviral 3? LTR exhibits both enhanced safety and acceptable efficiency of expression of antigenic proteins.Type: ApplicationFiled: March 15, 2007Publication date: September 25, 2008Inventors: Julianna Lisziewicz, Jianqing Xu, Franco Lori